ViaLase Inc.: A New Era in Glaucoma Treatment

ViaLase Inc., an innovative medtech startup focused on glaucoma treatment, is making notable changes in its leadership structure as it gears up for a commercial launch in both the U.S. and Europe. Dr. Tibor Juhasz, the company’s founder and former chief executive, will transition to the roles of president and chief technology officer. Shawn O’Neil, who previously served as chief commercial officer, will take the helm as the new CEO. In his statement, Juhasz expressed excitement about this leadership change, emphasizing the team’s dedication to delivering incision-free interventional glaucoma treatment to physicians and patients globally.

Innovating Glaucoma Treatments

ViaLase’s core technology aims to disrupt traditional methods for treating primary open-angle glaucoma. The ViaLase Laser System employs a unique approach—emitting short pulses of light to create microscopic channels in the eye. This innovative procedure aids in draining excess fluid, effectively reducing intraocular pressure. Following the receipt of CE Mark approval for its technology in July, ViaLase is preparing to embrace regulatory milestones that will ensure its products reach patients around the world. However, it anticipates further steps are needed, such as FDA approval in the U.S.

Leadership and Market Strategy

The recent leadership changes at ViaLase underline the company’s commitment to enhancing market execution and driving global commercialization. Shawn O’Neil comes with an impressive track record, boasting over three decades in the ophthalmic sector, including 22 years at Alcon Inc., one of the world’s leading medical device manufacturers. His extensive experience positions him well to guide ViaLase as it enters a crucial phase of its business. Taking over O’Neil’s former role as COO is Pete England, who previously held the vice president of global marketing position at ViaLase and has significant experience in the surgical glaucoma business from his tenure at Alcon.

European Launch and Partnerships

The company is set to launch its groundbreaking glaucoma treatment in Europe this summer, working in collaboration with established distributor partnerships like Global Surgical Service for Spain and Portugal, and Teleon Surgical for Germany and Austria. These strategic partnerships are crucial steps in establishing a foothold in international markets. Meanwhile, in the U.S., ViaLase is initiating a randomized, two-arm clinical study, a vital requirement for FDA approval. This dual approach signifies ViaLase’s commitment to both immediate international markets and long-term growth in its home country.

A Stellar Executive Team

ViaLase’s executive team includes renowned professionals in the ophthalmic field. Dr. Juhasz, a pioneer credited with breakthroughs leading to developments like LASIK, co-founded IntraLase, a notable Irvine medtech company. His expertise lends significant weight to ViaLase’s research and development initiatives. Tom Frinzi serves as the executive chairman and brings extensive experience to the table, having recently stepped down as CEO at Staar Surgical Co. He commended Juhasz for building a strong clinical organization that sets the groundwork for advancements in glaucoma care.

Financial Backing and Growth

ViaLase is also supported by notable investors, including Bill Link, a well-regarded venture capitalist associated with Flying L Partners and Versant Ventures. With over $75 million raised to date, ViaLase recently completed a $40 million Series C funding round, featuring participation from existing investors. This financial backing demonstrates confidence in ViaLase’s innovative approach and its potential to transform glaucoma treatment, paving the way for a new chapter in patient care.

As ViaLase moves forward with its commercialization plans, the dual focus on innovative technology and effective leadership will be key to its success in the competitive landscape of medical devices. The company’s vision to revolutionize glaucoma treatment stands poised to make a substantive impact on patient lives, transforming an area of healthcare that has remained relatively stagnant for years.